Core Viewpoint - WuXi AppTec's CAR-T cell therapy, Rikeolunase injection, is making progress in negotiations to be included in the commercial insurance innovative drug directory, which is expected to reduce the financial burden on patients and benefit more individuals [1] Group 1 - Rikeolunase injection is the first domestically approved Class 1 CAR-T therapy in China [1] - The pricing for the therapy post-launch is set at 1.29 million yuan per injection [1]

Core Viewpoint - WuXi AppTec's CAR-T cell therapy, Rukiyou Lunsai injection, is making significant progress in negotiations to be included in the commercial health insurance innovative drug directory, which is expected to reduce the financial burden on patients and benefit more individuals [1] Company Summary - WuXi AppTec's Rukiyou Lunsai injection is the first domestically approved Class 1 CAR-T therapy in China [1] - The pricing for the therapy post-launch is set at 1.29 million yuan per injection [1]

Group 1: Company Strategy and Goals - The overall business goal for 2025 is to achieve restorative growth and maintain stable development [3] - The company aims to enhance the sales proportion of growth hormone water injections and expand the indications for growth hormone [3] - The company plans to accelerate the production capacity of the cancer drug Trastuzumab (Ansatin) and deepen brand building and market expansion [3] Group 2: Product Development and Clinical Trials - The clinical trial for "AK2017 Injection" (recombinant human growth hormone-Fc fusion protein injection) has successfully completed Phase II enrollment, with discussions for Phase III trial already held [3] - The company is actively promoting clinical trials for interferon spray and inhalation agents, targeting respiratory infections and gynecological diseases [3] - The "AK1008 Project" (human interferon α2b spray) is in Phase II trials for treating viral infections in children [3] Group 3: Competitive Landscape - Currently, there are 5 companies producing short-acting growth hormones, and several companies are expected to launch long-acting growth hormones [4] - The market for growth hormones is competitive but the overall pricing system remains stable [4] - The strategic partnership with Weisheng Pharmaceutical aims to cover the long-acting growth hormone market and enhance the company's competitiveness in children's growth and development [7] Group 4: Innovation and Collaborations - The company is developing several innovative drugs, including "HuA21 Injection" targeting HER2, which has shown promising safety and efficacy in early trials [4] - Collaboration with Afana Company on "AFN0328 Injection" for HPV precancerous lesions is in Phase I trials, with plans for further mRNA drug development [5] - The company is also involved in CAR-T cell therapy research through its investment in Boshengji Company, which has received implicit approval for clinical trials [5] Group 5: Market Expansion and Future Plans - The company is preparing to expand its international market presence by building FDA and EU-compliant production lines and engaging with foreign distributors [8] - The exclusive agency agreement with Baoji Pharmaceutical for the innovative drug "SJ02" aims to enhance the company's product matrix in the assisted reproduction field [8] - The company anticipates that the launch of long-acting growth hormones and long-acting follicle-stimulating hormones will provide new growth points for its business [8]